Is BON a good stock to buy right now?

Based on our 6-factor quantitative model, Bon Natural Life Ltd (BON) receives a "Reduce" rating with a composite score of 34.8/100. It is ranked #3,229 out of 4,446 stocks. Key factor scores: Quality 26/100, Value 22/100, Momentum 51/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for BON?

Bon Natural Life Ltd (BON) has a "Reduce" rating and 2-star score. The composite score of 34.8 ranks it #3,229 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is BON in?

Bon Natural Life Ltd operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $10 million. It is classified as a micro-cap stock.

Does BON pay a dividend?

BON does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is BON's P/E ratio?

P/E ratio data is not currently available for BON, which may indicate the company is not yet profitable.

How profitable is BON?

BON's quality factor score is 26/100. Gross margin: 20.8%. ROE: -14.2% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is BON valued compared to peers?

BON's value factor score is 22/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is BON's debt level?

BON's debt-to-equity ratio is 21%. Sector average: 32%. Low leverage suggests conservative financial management.

BON has a beta of 0.75, meaning it is less volatile than the market. Stability score: 25/100.

Does BON have high short interest?

BON's short interest factor score is 64/100 (higher = less short selling). Moderate short interest.

BON Stock Analysis: Top Micro-Cap Reduce (Score 34.8/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
BON	+0.77%	+2.34%	-12.08%	-17.61%	+2,058.15%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.84%	-1.26%	-12.42%	-17.25%	+2,028.63%	-	-	-
Alpha vs Sector	+2.12%	+2.00%	-8.27%	-12.77%	+2,048.95%	-	-	-

Metric	BON	Benchmark
P/E Ratio	-1.3x	-106%
EV/EBITDA	—	—
Price / Book	0.2x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
BON Bon Natural Life Ltd	35	26	22	51	-	-14.2%	20.8%	-11.0%	-	21.0x	$10M

Key Ratio	TTM	2025	2024	2023	2022	2021	2020
Gross Margin %	0.2%	0.2%	0.3%	0.3%	0.3%	0.3%	0.3%
Operating Margin %	-0.1%	-0.1%	0.1%	0.2%	0.2%	0.2%	0.2%
EBITDA Margin %	-0.0%	-0.0%	0.1%	0.2%	0.3%	0.2%	0.2%
Net Margin %	-0.1%	-0.1%	0.0%	0.2%	0.2%	0.2%	0.2%
FCF Margin %	0.7%	0.7%	-32.4%	-2.3%	-0.7%	-1.7%	14.3%
ROE %	-0.1%	-0.0%	0.0%	0.1%	0.2%	0.2%	0.3%
ROA %	-0.1%	-0.0%	0.0%	0.1%	0.2%	0.1%	0.1%
ROIC %	-1.9%	-1.9%	2.9%	12.0%	15.4%	15.9%	17.7%

Line Item	TTM	2025	2024	2023	2022	2021	2020
	$19M	$19M	$24M	$30M	$30M	$25M	$18M
	$4M	$4M	$7M	$9M	$9M	$7M	$5M
Gross Margin	20.8%	20.8%	29.8%	29.9%	31.5%	27.9%	28.5%
	—	$754K	$2M	$298K	$425K	$249K	$205K
Depreciation	—	$1M	$1M	$1M	$540K	$332K	$231K
	-$2M	-$2M	$2M	$6M	$7M	$5M	$3M
EBIT	-$2M	-$2M	$2M	$6M	$7M	$5M	$3M
EBITDA	-$59K	-$59K	$2M	$7M	$8M	$6M	$4M
Operating Margin	-8.7%	-8.7%	7.9%	20.1%	22.1%	21.2%	19.0%
EBITDA Margin	-0.3%	-0.3%	9.6%	23.6%	27.9%	24.4%	23.1%
	—	$366K	$303K	$238K	$447K	$417K	$329K
	—	$339K	$351K	$1M	$1M	$821K	$556K
	-$2M	-$2M	$345K	$5M	$6M	$5M	$3M
Net Margin	-11.0%	-11.0%	1.5%	15.4%	20.9%	18.1%	17.0%
	$-0.72	$-0.72	$0.17	$5.03	$0.75	$0.69	$0.58
Diluted EPS	$-0.72	$-0.72	$0.17	$5.03	$0.75	$0.69	$0.58

Bon Natural Life Ltd (BON) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Bon Natural Life Ltd Do?

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands. Bon Natural Life Ltd (BON) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Yong W. Hu and employs approximately 100 people. With a market capitalization of $10M, BON is one of the notable companies in the Healthcare sector.

Bon Natural Life Ltd (BON) Stock Rating — Reduce (April 2026)

As of April 2026, Bon Natural Life Ltd receives a Reduce rating with a composite score of 34.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BON ranks #3,229 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Bon Natural Life Ltd ranks #487 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BON Stock Price and 52-Week Range

Bon Natural Life Ltd (BON) currently trades at $1.31. The stock gained $0.01 (0.8%) in the most recent trading session. The 52-week high for BON is $3.40, which means the stock is currently trading -61.5% from its annual peak. The 52-week low is $0.05, putting the stock 2584.4% above its annual trough. Recent trading volume was 2K shares, suggesting relatively thin trading activity.

Is BON Overvalued or Undervalued? — Valuation Analysis

Bon Natural Life Ltd (BON) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.19x, versus the sector average of 2.75x. The price-to-sales ratio is 0.14x, compared to 1.66x for the average Healthcare stock.

At current multiples, Bon Natural Life Ltd trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Bon Natural Life Ltd Profitability — ROE, Margins, and Quality Score

Bon Natural Life Ltd (BON) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -14.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -9.6% versus the sector average of -33.1%.

On a margin basis, Bon Natural Life Ltd reports gross margins of 20.8%, compared to 71.5% for the sector. The operating margin is -8.7% (sector: -66.1%). Net profit margin stands at -11.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BON Debt, Balance Sheet, and Financial Health

Bon Natural Life Ltd has a debt-to-equity ratio of 21.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $12M. Cash and equivalents stand at $4M.

BON has a beta of 0.75, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Bon Natural Life Ltd is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Bon Natural Life Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, Bon Natural Life Ltd reported revenue of $19M and earnings per share (EPS) of $-0.72. Net income for the quarter was $-2M. Gross margin was 20.8%. Operating income came in at $-2M.

In FY 2025, Bon Natural Life Ltd reported revenue of $19M and earnings per share (EPS) of $-0.72. Net income for the quarter was $-2M. Gross margin was 20.8%. Revenue grew -21.7% year-over-year compared to FY 2024. Operating income came in at $-2M.

In FY 2024, Bon Natural Life Ltd reported revenue of $24M and earnings per share (EPS) of $0.17. Net income for the quarter was $345,248. Gross margin was 29.8%. Revenue grew -19.2% year-over-year compared to FY 2023. Operating income came in at $2M.

In FY 2023, Bon Natural Life Ltd reported revenue of $30M and earnings per share (EPS) of $5.03. Net income for the quarter was $5M. Gross margin was 29.9%. Revenue grew -1.3% year-over-year compared to FY 2022. Operating income came in at $6M.

Over the past 7 quarters, Bon Natural Life Ltd has demonstrated a growth trajectory, with revenue expanding from $18M to $19M. Investors analyzing BON stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BON Dividend Yield and Income Analysis

Bon Natural Life Ltd (BON) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BON Momentum and Technical Analysis Profile

Bon Natural Life Ltd (BON) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 18/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

BON vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Bon Natural Life Ltd (BON) ranks #487 out of 838 stocks based on the Blank Capital composite score. This places BON in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BON against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BON vs S&P 500 (SPY) comparison to assess how Bon Natural Life Ltd stacks up against the broader market across all factor dimensions.

BON Next Earnings Date

No upcoming earnings date has been announced for Bon Natural Life Ltd (BON) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BON? — Investment Thesis Summary

The quantitative profile for Bon Natural Life Ltd suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. High volatility (stability score 25/100) increases portfolio risk.

In summary, Bon Natural Life Ltd (BON) earns a Reduce rating with a composite score of 34.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BON stock.

Related Resources for BON Investors

Explore more research and tools: BON vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BON head-to-head with peers: BON vs AZN, BON vs SLGL, BON vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

BONDUELLE - Monthly statement of the number of shares and voting rights

11 Materials Stocks Moving In Wednesday's After-Market Session

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks